Value of Analysing Under-utilised Leftover Tissue (VauLT)
NCT03832062
Summary
Intratumour heterogeneity is well recognized in multiple cancer types and ultimately leads to therapeutic resistance. It also limits the ability of small samples to represent the whole tumour, having implications for diagnosis, molecular analysis and understanding of the tumour immune microenvironment. By blending- 'homogenizing'- leftover tumour tissue in excess of that required for diagnosistic purposes, one may create a more representative sample for analysis.
Eligibility
Inclusion Criteria: 1. Leftover formalin-fixed tissue (ie that would be otherwise discarded by histopathology) from cancer surgery. 2. Tissues for Research consent has been provided. 3. Patient age \>18yo. 4. Minimum of 1 gram of residual tumour remaining in leftover surgical tissue 5. Minimum of 1 gram of normal tissue present. Exclusion Criteria: 1. Advanced Practitioner in histological dissection deems tumour sample to be inadequate. 2. Leftover surgical tumour tissue greater than 20kg.
Conditions2
Browse More Trials
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.
NCT03832062